Abemaciclib, LY2835219 (CAS 1231929-97-7)

Application and positioning

Abemaciclib is an orally active, selective CDK4/6 inhibitor that arrests the cell cycle at the G1/S checkpoint in hormone-receptor-positive tumour cells. It is formulated into oral tablets for HR-positive, HER2-negative advanced or metastatic breast cancer, given as monotherapy or combined with endocrine therapy. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Afatinib Dimaleate (CAS 850140-73-7)
• Alectinib Hydrochloride (CAS 1256589-74-8)
• Axitinib (CAS 319460-85-0)
• Cabozantinib Malate (CAS 1140909-48-3)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.